[Treatment of peritoneal carcinomatosis with surgery and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC): new aspects and validated indications].
Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is now an entire part of treatment of peritoneal dissemination of colorectal malignancy, and it's possible to hope prolonged survival. This treatment is more and more codified. Four indications are recognized by some tree national evaluation committees: the French ANAES, the British NICE and the Canadian CEPO: colorectal carcinoma, carcinoma of the appendix, pseudomyxoma peritonei and mesothelioma. Last big published series results show a decrease of morbidity and mortality and interest of using new drugs like oxaliplatine. Indications have to be more homogeneous and based on evidences.
Eveno
Clarisse
C
Département médicochirurgical de pathologie digestive, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France.
Dagois
Sophie
S
Guillot
Emmanuelle
E
Gornet
Jean-Marc
JM
Pocard
Marc
M
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D006979:Hyperthermia, Induced; D008654:Mesothelioma / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011553:Pseudomyxoma Peritonei / Q000628:therapy
D000970:Antineoplastic Agents